Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

NCT01392443 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis (MF)
Post-Polycythemia Vera (PV) MF
Post-Essential Thrombocythemia (ET) MF

Interventions

DRUG: Ruxolitinib

Sponsor

Novartis Pharmaceuticals